Search

Your search keyword '"Rilo, HLR"' showing total 38 results
Start Over Author "Rilo, HLR" Database OAIster
38 results on '"Rilo, HLR"'

1. Enhancement of donor cell chimerism in whole organ allograft recipients by adjuvant bone marrow transplantation

Author

Rao, AS, Fontes, P, Zeevi, A, Rugeles, M, Shapiro, R, Jordan, M, Corry, R, Dodson, F, Rilo, HLR, Rastellini, C, Aitouche, A, Rosner, G, Trucco, M, Demetris, AJ, Fung, JJ, Starzl, TE, Rao, AS, Fontes, P, Zeevi, A, Rugeles, M, Shapiro, R, Jordan, M, Corry, R, Dodson, F, Rilo, HLR, Rastellini, C, Aitouche, A, Rosner, G, Trucco, M, Demetris, AJ, Fung, JJ, and Starzl, TE

Published
1995

4. Enhancement of donor cell chimerism in whole organ allograft recipients by adjuvant bone marrow transplantation

Author

Rao, AS, Fontes, P, Zeevi, A, Rugeles, M, Shapiro, R, Jordan, M, Corry, R, Dodson, F, Rilo, HLR, Rastellini, C, Aitouche, A, Rosner, G, Trucco, M, Demetris, AJ, Fung, JJ, Starzl, TE, Rao, AS, Fontes, P, Zeevi, A, Rugeles, M, Shapiro, R, Jordan, M, Corry, R, Dodson, F, Rilo, HLR, Rastellini, C, Aitouche, A, Rosner, G, Trucco, M, Demetris, AJ, Fung, JJ, and Starzl, TE

Published
1995

7. Simultaneous solid organ, bone marrow and islet allotransplantation in type I diabetic patients

Author

Carroll, PB, Fontes, P, Rao, AS, Ricordi, C, Rilo, HLR, Zeevi, A, Trucco, M, Shapiro, R, Rybka, WB, Scantlebury, V, Dodson, FS, Tzakis, AG, Rudert, WA, Behboo, R, Karatzas, T, Khan, R, Demetris, AJ, Flohr, J, Fung, JJ, Starzl, TE, Carroll, PB, Fontes, P, Rao, AS, Ricordi, C, Rilo, HLR, Zeevi, A, Trucco, M, Shapiro, R, Rybka, WB, Scantlebury, V, Dodson, FS, Tzakis, AG, Rudert, WA, Behboo, R, Karatzas, T, Khan, R, Demetris, AJ, Flohr, J, Fung, JJ, and Starzl, TE

Published
1994

8. Protective effects of the lazaroid U74500A and lidoflazine on liver preservation with UW solution

Author

Jacobsson, J, Sundberg, R, Rilo, HLR, Gasbarrini, A, Starzl, TE, Van Thiel, D, Jacobsson, J, Sundberg, R, Rilo, HLR, Gasbarrini, A, Starzl, TE, and Van Thiel, D

Abstract

The effect of adding a 21-aminosteroid, U74500A, and a Ca2+ antagonist, lidoflazine, alone and together to UW solution was assessed in a rat liver preservation model. Following preservation, the livers were reperfused using a closed circuit, and the release of hepatocellular enzymes (ASAT, ALAT, and LDH) into the perfusate was determined with increasing time. Both drugs reduced the amount of enzymes lost from the liver. The combination of the two drugs was better than either drug alone. These data suggest that both agents may be of value in organ preservation for clinical liver transplantation. © 1993 Springer-Verlag.

Published
1993

9. Survival of human hepatocellular aggregates in athymic mice

Author

Ricordi, C, Zeng, Y, Carr, B, Carroll, P, Rilo, HLR, Demetris, AJ, Alejandro, R, Bereiter, DR, Fung, JJ, Tzakis, A, Starzl, TE, Ricordi, C, Zeng, Y, Carr, B, Carroll, P, Rilo, HLR, Demetris, AJ, Alejandro, R, Bereiter, DR, Fung, JJ, Tzakis, A, and Starzl, TE

Published
1992

12. Outcome of human islet isolation and allotransplantation in 20 consecutive cases.

Author

Ricordi, C, Carroll, P, Tzakis, A, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Demetris, AJ, Mintz, DH, Starzl, TE, Ricordi, C, Carroll, P, Tzakis, A, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Demetris, AJ, Mintz, DH, and Starzl, TE

Abstract

This report provides our initial experience on islet isolation and intrahepatic allotransplantation in 20 patients. In Group 1, 10 patients underwent combined liver-islet allotransplantation following upper-abdominal exenteration for cancer. One patient underwent pancreatic islet allograft after near total pancreatectomy for chronic pancreatitis. In Group 2, 3 Type I diabetic patients received a combined liver-islet allograft for cirrhosis and diabetes. In Group 3, 7 Type I diabetic patients received 8 combined cadaveric kidney-islet grafts (one retransplant) for end stage renal disease. The islets were separated by a modification of the automated method for human islet isolation and the preparations were infused into the portal vein. Immunosuppression was with FK-506 (Group 1) plus steroids (Groups 2 and 3). Six patients in Group 1 did not require insulin treatment for 5 to >16 mo. In Groups 2 and 3 none of the patients became insulin-independent, although ongoing C-peptide secretion, decreased insulin requirement and stabilization of diabetes were observed. Our results indicate that islet transplantation is most effective in pancreatectomy induced diabetes. However, rejection is still a major factor limiting the clinical application of islet transplantation in patients with Type I diabetes mellitus. Other factors such as steroid treatment may contribute to deteriorate islet engraftment and/or function.

Published
1992

14. Human islet allotransplantation in 18 diabetic patients

Author

Ricordi, C, Tzakis, A, Carroll, P, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Demetris, AJ, Bereiter, DR, Mintz, DH, Starzl, TE, Ricordi, C, Tzakis, A, Carroll, P, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Demetris, AJ, Bereiter, DR, Mintz, DH, and Starzl, TE

Published
1992

16. Long-term survival of donor-specific pancreatic islet xenografts in fully xenogeneic chimeras (Wf rat → B10 mouse)

Author

Zeng, Y, Ricordi, C, Tzakis, A, Rilo, HLR, Carroll, PB, Starzl, TE, Ildstad, ST, Zeng, Y, Ricordi, C, Tzakis, A, Rilo, HLR, Carroll, PB, Starzl, TE, and Ildstad, ST

Abstract

We recently reported that reconstitution of lethally irradiated BIO mouse recipients with 40x10s untreated WF rat bone marrow cells resulted in stable fully xenogeneic chimerism (WF rat → B10 mouse). In these animals, the tolerance induced for skin xenografts was highly MHC specific in that donor-specific WF rat skin grafts were significantly prolonged while MHC-dispar-ate third-party xenografts were rapidly rejected (median survival time [MST] = 9 days). We have now examined whether islet cell xenografts placed under the renal capsule of chimeras rendered diabetic with strep-tozotocin would be accepted and remain functional to maintain euglycemia. Animals were prepared, typed for chimerism at 6 weeks, and diabetes induced with strep-tozotocin. Donor-specific WF (RtlA") islet cell xenografts were significantly prolonged (MST >180 days) in WF → B10 chimeras, while MHC-disparate third-party F344 rat (RtlA1) grafts were rejected with a time course similar to unmanipulated BIO mice (MST=8 days). The transplanted donor-specific islet cells were functional to maintain euglycemia, since removal of the grafts at from 100 to 180 days in selected individual chimeras uniformly resulted in return of the diabetic state. These data suggest that donor-specific islet cell xenografts are accepted and remain functional in mice rendered tolerant to rat xenoantigens following bone marrow transplantation. © 1992 by Williams and Wilkins.

Published
1992

18. Islet transplantation in diabetes: The Pittsburgh experience

Author

Ricordi, C, Carroll, P, Tzakis, A, Alejandro, R, Zeng, Y, Rilo, HLR, Fontes, PAC, Shapiro, R, Fung, JJ, Starzl, TE, Ricordi, C, Carroll, P, Tzakis, A, Alejandro, R, Zeng, Y, Rilo, HLR, Fontes, PAC, Shapiro, R, Fung, JJ, and Starzl, TE

Published
1992

26. Outcome of human islet isolation and allotransplantation in 20 consecutive cases.

Author

Ricordi, C, Carroll, P, Tzakis, A, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Demetris, AJ, Mintz, DH, Starzl, TE, Ricordi, C, Carroll, P, Tzakis, A, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Demetris, AJ, Mintz, DH, and Starzl, TE

Abstract

This report provides our initial experience on islet isolation and intrahepatic allotransplantation in 20 patients. In Group 1, 10 patients underwent combined liver-islet allotransplantation following upper-abdominal exenteration for cancer. One patient underwent pancreatic islet allograft after near total pancreatectomy for chronic pancreatitis. In Group 2, 3 Type I diabetic patients received a combined liver-islet allograft for cirrhosis and diabetes. In Group 3, 7 Type I diabetic patients received 8 combined cadaveric kidney-islet grafts (one retransplant) for end stage renal disease. The islets were separated by a modification of the automated method for human islet isolation and the preparations were infused into the portal vein. Immunosuppression was with FK-506 (Group 1) plus steroids (Groups 2 and 3). Six patients in Group 1 did not require insulin treatment for 5 to >16 mo. In Groups 2 and 3 none of the patients became insulin-independent, although ongoing C-peptide secretion, decreased insulin requirement and stabilization of diabetes were observed. Our results indicate that islet transplantation is most effective in pancreatectomy induced diabetes. However, rejection is still a major factor limiting the clinical application of islet transplantation in patients with Type I diabetes mellitus. Other factors such as steroid treatment may contribute to deteriorate islet engraftment and/or function.

Published
1992

27. Long-term survival of donor-specific pancreatic islet xenografts in fully xenogeneic chimeras (Wf rat → B10 mouse)

Author

Zeng, Y, Ricordi, C, Tzakis, A, Rilo, HLR, Carroll, PB, Starzl, TE, Ildstad, ST, Zeng, Y, Ricordi, C, Tzakis, A, Rilo, HLR, Carroll, PB, Starzl, TE, and Ildstad, ST

Abstract

We recently reported that reconstitution of lethally irradiated BIO mouse recipients with 40x10s untreated WF rat bone marrow cells resulted in stable fully xenogeneic chimerism (WF rat → B10 mouse). In these animals, the tolerance induced for skin xenografts was highly MHC specific in that donor-specific WF rat skin grafts were significantly prolonged while MHC-dispar-ate third-party xenografts were rapidly rejected (median survival time [MST] = 9 days). We have now examined whether islet cell xenografts placed under the renal capsule of chimeras rendered diabetic with strep-tozotocin would be accepted and remain functional to maintain euglycemia. Animals were prepared, typed for chimerism at 6 weeks, and diabetes induced with strep-tozotocin. Donor-specific WF (RtlA") islet cell xenografts were significantly prolonged (MST >180 days) in WF → B10 chimeras, while MHC-disparate third-party F344 rat (RtlA1) grafts were rejected with a time course similar to unmanipulated BIO mice (MST=8 days). The transplanted donor-specific islet cells were functional to maintain euglycemia, since removal of the grafts at from 100 to 180 days in selected individual chimeras uniformly resulted in return of the diabetic state. These data suggest that donor-specific islet cell xenografts are accepted and remain functional in mice rendered tolerant to rat xenoantigens following bone marrow transplantation. © 1992 by Williams and Wilkins.

Published
1992

29. Islet transplantation in diabetes: The Pittsburgh experience

Author

Ricordi, C, Carroll, P, Tzakis, A, Alejandro, R, Zeng, Y, Rilo, HLR, Fontes, PAC, Shapiro, R, Fung, JJ, Starzl, TE, Ricordi, C, Carroll, P, Tzakis, A, Alejandro, R, Zeng, Y, Rilo, HLR, Fontes, PAC, Shapiro, R, Fung, JJ, and Starzl, TE

Published
1992

30. Survival of human hepatocellular aggregates in athymic mice

Author

Ricordi, C, Zeng, Y, Carr, B, Carroll, P, Rilo, HLR, Demetris, AJ, Alejandro, R, Bereiter, DR, Fung, JJ, Tzakis, A, Starzl, TE, Ricordi, C, Zeng, Y, Carr, B, Carroll, P, Rilo, HLR, Demetris, AJ, Alejandro, R, Bereiter, DR, Fung, JJ, Tzakis, A, and Starzl, TE

Published
1992

32. Human islet allotransplantation in 18 diabetic patients

Author

Ricordi, C, Tzakis, A, Carroll, P, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Demetris, AJ, Bereiter, DR, Mintz, DH, Starzl, TE, Ricordi, C, Tzakis, A, Carroll, P, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Demetris, AJ, Bereiter, DR, Mintz, DH, and Starzl, TE

Published
1992

33. Effect of FK 506 on function of human islets of Langerhans

Author

Rilo, HLR, Zeng, Y, Alejandro, R, Carroll, PB, Bereiter, D, Venkataramanan, R, Tzakis, AG, Starzl, TE, Ricordi, C, Rilo, HLR, Zeng, Y, Alejandro, R, Carroll, PB, Bereiter, D, Venkataramanan, R, Tzakis, AG, Starzl, TE, and Ricordi, C

Published
1991

35. Human islet allotransplantation under FK 506

Author

Ricordi, C, Tzakis, A, Carroll, P, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Mintz, DH, Starzl, TE, Ricordi, C, Tzakis, A, Carroll, P, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Mintz, DH, and Starzl, TE

Published
1991

37. Effect of FK 506 on function of human islets of Langerhans

Author

Rilo, HLR, Zeng, Y, Alejandro, R, Carroll, PB, Bereiter, D, Venkataramanan, R, Tzakis, AG, Starzl, TE, Ricordi, C, Rilo, HLR, Zeng, Y, Alejandro, R, Carroll, PB, Bereiter, D, Venkataramanan, R, Tzakis, AG, Starzl, TE, and Ricordi, C

Published
1991

38. Human islet allotransplantation under FK 506

Author

Ricordi, C, Tzakis, A, Carroll, P, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Mintz, DH, Starzl, TE, Ricordi, C, Tzakis, A, Carroll, P, Zeng, Y, Rilo, HLR, Alejandro, R, Shapiro, R, Fung, JJ, Mintz, DH, and Starzl, TE

Published
1991

Catalog

Books, media, physical & digital resources
See catalog results